CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 20, Issue 11, Pages 2764
Publisher
MDPI AG
Online
2019-06-06
DOI
10.3390/ijms20112764
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CD28-ζ CAR T cells resist TGF-β repression through IL-2 signaling which can be mimicked by IL-7 and an engineered IL-7/IL-2Rβ autocrine loop
- (2018) Viktória Golumba-Nagy et al. MOLECULAR THERAPY
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy
- (2018) Serena Pellegatta et al. Science Translational Medicine
- Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types
- (2018) Kristina M. Ilieva et al. Frontiers in Immunology
- CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum
- (2018) Asen Bagashev et al. MOLECULAR AND CELLULAR BIOLOGY
- Tumors evading CARs—the chase is on
- (2018) Sarwish Rafiq et al. NATURE MEDICINE
- Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
- (2018) Elena J. Orlando et al. NATURE MEDICINE
- Tumor Antigen Escape from CAR T-cell Therapy
- (2018) Robbie G. Majzner et al. Cancer Discovery
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic T cell engineering
- (2017) Michel Sadelain et al. NATURE
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches
- (2017) Amanda C. Winters et al. Frontiers in Pediatrics
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
- (2016) R. Gardner et al. BLOOD
- A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein
- (2016) Manal Amoury et al. INTERNATIONAL JOURNAL OF CANCER
- An essential role for the IL-2 receptor in Treg cell function
- (2016) Takatoshi Chinen et al. NATURE IMMUNOLOGY
- The Role of NG2 Proteoglycan in Glioma
- (2016) Sridevi Yadavilli et al. Translational Oncology
- Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy
- (2016) Fabiana Perna et al. Translational Cancer Research
- MLL1 and MLL1 fusion proteins have distinct functions in regulating leukemic transcription program
- (2016) Jing Xu et al. Cell Discovery
- Generation of CD8+T cells expressing two additional T-cell receptors (TETARs) for personalised melanoma therapy
- (2015) Sandra Höfflin et al. CANCER BIOLOGY & THERAPY
- Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone
- (2015) Christian Krug et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CAR therapy: the CD19 paradigm
- (2015) Michel Sadelain JOURNAL OF CLINICAL INVESTIGATION
- Theranostic Impact of NG2/CSPG4 Proteoglycan in Cancer
- (2015) Pier Andrea Nicolosi et al. Theranostics
- A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor
- (2014) Christian Krug et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A CSPG4-specific immunotoxin kills rhabdomyosarcoma cells and binds to primary tumor tissues
- (2014) Hannes Brehm et al. CANCER LETTERS
- IL-2: The First Effective Immunotherapy for Human Cancer
- (2014) S. A. Rosenberg JOURNAL OF IMMUNOLOGY
- Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells
- (2014) Rachel E Beard et al. Journal for ImmunoTherapy of Cancer
- T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo
- (2013) C. Geldres et al. CLINICAL CANCER RESEARCH
- Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
- (2013) Cor HJ Lamers et al. MOLECULAR THERAPY
- Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
- (2012) W. Haso et al. BLOOD
- CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
- (2012) Z. Rivera et al. CLINICAL CANCER RESEARCH
- Functional Characterization of an scFv-Fc Antibody that Immunotherapeutically Targets the Common Cancer Cell Surface Proteoglycan CSPG4
- (2011) X. Wang et al. CANCER RESEARCH
- CD28 Costimulation Impairs the Efficacy of a Redirected T-cell Antitumor Attack in the Presence of Regulatory T cells Which Can Be Overcome by Preventing Lck Activation
- (2011) David M Kofler et al. MOLECULAR THERAPY
- Analysis of the Role of Hematopoietic Stem-Cell Transplantation in Infants With Acute Lymphoblastic Leukemia in First Remission andMLLGene Rearrangements: A Report From the Children's Oncology Group
- (2010) ZoAnn E. Dreyer et al. JOURNAL OF CLINICAL ONCOLOGY
- CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer
- (2010) Xinhui Wang et al. JNCI-Journal of the National Cancer Institute
- Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo
- (2010) Marco de Bruyn et al. Molecular Cancer
- A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells
- (2009) Michael Schwenkert et al. MELANOMA RESEARCH
- Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies
- (2008) Allison S. Drake et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search